Prognostic Value of EGFR Exon-20 Insertions in Czech Patients
With Advanced Non-small Cell Lung Cancer

J 2021

Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer

SKŘIČKOVÁ, Jana, M PESEK, P OPALKA, L KOUBKOVA, M ZEMANOVA et. al.

Basic information

Original name

Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer

Authors

Edition

Anticancer Research, Athens, International Institute of Anticancer Research, 2021, 0250-7005

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.435

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.21873/anticanres.15378

UT WoS

000720235500011

Keywords in English

EGFR exon-20 insertions; NSCLC; prognostic values; RWE

Abstract

V originále

Background/Aim: Per literature, patients with epidermal growth factor receptor (EGFR) exon-20 insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-world data to examine the prognostic and predictive value of these mutations. Patients and Methods: We conducted a retrospective cohort study using Czech TULUNG Registry data, with data on multiple mutation types, collected in 2011-2020. Results: We analyzed 554 (95.85%) patients with EGFR exon-19 deletions or exon-21 L858R substitutions and 24 (4.15%) patients with exon-20 insertions who received first-line high-value therapies. We summarized clinical characteristics and outcomes in all patients and by cohort. The risk of progression was statistically significantly higher (86%) in the exon-20 insertion cohort compared to the cohort with other mutations. Although not statistically significant, the risk of death was 44% higher in patients with exon-20 insertions. Conclusion: Advanced NSCLC patients with rare EGFR exon-20 insertions have a high risk of progression.

Citovat

SKŘIČKOVÁ, Jana, M PESEK, P OPALKA, L KOUBKOVA, M ZEMANOVA, M HRNCIARIK, J BLAZEK, M SVATON, J KREJCI, H COUPKOVA, D DOLEZAL, T TUZOVA, L HOLUBEC, P MAHADEVIA, K SANDSTROM, P KUNOVSZKI, M BARINOVA, K HURDALKOVA, O FISCHER, M CERNOVSKA and M BRATOVA. Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer. Anticancer Research. Athens: International Institute of Anticancer Research, 2021, vol. 41, No 11, p. 5625-5634. ISSN 0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.15378.

@article{1807829,
   author = {Skřičková, Jana and Pesek, M and Opalka, P and Koubkova, L and Zemanova, M and Hrnciarik, M and Blazek, J and Svaton, M and Krejci, J and Coupkova, H and Dolezal, D and Tuzova, T and Holubec, L and Mahadevia, P and Sandstrom, K and Kunovszki, P and Barinova, M and Hurdalkova, K and Fischer, O and Cernovska, M and Bratova, M},
   article_location = {Athens},
   article_number = {11},
   doi = {http://dx.doi.org/10.21873/anticanres.15378},
   keywords = {EGFR exon-20 insertions; NSCLC; prognostic values; RWE},
   language = {eng},
   issn = {0250-7005},
   journal = {Anticancer Research},
   note = {Bez afiliace k MU.},
   title = {Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer},
   volume = {41},
   year = {2021}
}

TY  - JOUR
ID  - 1807829
AU  - Skřičková, Jana - Pesek, M - Opalka, P - Koubkova, L - Zemanova, M - Hrnciarik, M - Blazek, J - Svaton, M - Krejci, J - Coupkova, H - Dolezal, D - Tuzova, T - Holubec, L - Mahadevia, P - Sandstrom, K - Kunovszki, P - Barinova, M - Hurdalkova, K - Fischer, O - Cernovska, M - Bratova, M
PY  - 2021
TI  - Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer
JF  - Anticancer Research
VL  - 41
IS  - 11
SP  - 5625-5634
EP  - 5625-5634
PB  - International Institute of Anticancer Research
SN  - 02507005
N1  - Bez afiliace k MU.
KW  - EGFR exon-20 insertions
KW  - NSCLC
KW  - prognostic values
KW  - RWE
N2  - Background/Aim: Per literature, patients with epidermal growth factor receptor (EGFR) exon-20 insertions respond poorly to tyrosine kinase inhibitors (TKIs). This study analyzed real-world data to examine the prognostic and predictive value of these mutations. Patients and Methods: We conducted a retrospective cohort study using Czech TULUNG Registry data, with data on multiple mutation types, collected in 2011-2020. Results: We analyzed 554 (95.85%) patients with EGFR exon-19 deletions or exon-21 L858R substitutions and 24 (4.15%) patients with exon-20 insertions who received first-line high-value therapies. We summarized clinical characteristics and outcomes in all patients and by cohort. The risk of progression was statistically significantly higher (86%) in the exon-20 insertion cohort compared to the cohort with other mutations. Although not statistically significant, the risk of death was 44% higher in patients with exon-20 insertions. Conclusion: Advanced NSCLC patients with rare EGFR exon-20 insertions have a high risk of progression.
ER  -

SKŘIČKOVÁ, Jana, M PESEK, P OPALKA, L KOUBKOVA, M ZEMANOVA, M HRNCIARIK, J BLAZEK, M SVATON, J KREJCI, H COUPKOVA, D DOLEZAL, T TUZOVA, L HOLUBEC, P MAHADEVIA, K SANDSTROM, P KUNOVSZKI, M BARINOVA, K HURDALKOVA, O FISCHER, M CERNOVSKA and M BRATOVA. Prognostic Value of EGFR Exon-20 Insertions in Czech Patients With Advanced Non-small Cell Lung Cancer. \textit{Anticancer Research}. Athens: International Institute of Anticancer Research, 2021, vol.~41, No~11, p.~5625-5634. ISSN~0250-7005. Available from: https://dx.doi.org/10.21873/anticanres.15378.

Detailed Information on Publication Record